DermTech's low P/S ratio is likely due to limited future growth expectations. Poor revenue performance and a lower-than-industry growth forecast have reduced investor willingness to pay more for the stock. A significant change in fortune is needed for a higher P/S ratio.
$DermTech(DMTK.US)$DermTech Announces Restructuring Actions And Emphasis On Growing Revenue For DermTech Melanoma Test ; Co. To Reduce 15% Of Workforce, Expects ~$40M In Total Operating Expense Reductions
$DermTech(DMTK.US)$DermTech Announces Topline Results From Study Evaluating DermTech Melanoma Test Across All Skin Types; Negative Predictive Value Higher Than 99% Regardless Of Skin Type
QUICK SCALP 5 $DMTK — STOCK & OPTION PLAY ALERT ON: $5.08 ON THE WATCH: $5.15 🥇 SIGNED OF MORE UPTREND: $5.23 NEED IT TO BREAK OVER: $5.37 key indicator for MORE uptrend $5.52 confirmation uptrend - $5.73 mini breakout - $5.95.$DermTech(DMTK.US)$
DermTech股票討論區
ALERT ON: $5.08
ON THE WATCH: $5.15
🥇 SIGNED OF MORE UPTREND: $5.23
NEED IT TO BREAK OVER: $5.37
key indicator for MORE uptrend $5.52
confirmation uptrend - $5.73
mini breakout - $5.95. $DermTech(DMTK.US)$
暫無評論